Tags: Merck Drug Trial

Merck Stops Trial for Potential Blood Thinner

Thursday, 13 Jan 2011 12:06 PM

Shares of Merck & Co. are falling after the drugmaker says it has halted one late-stage trial of a potential blood thinner and will immediately stop giving the drug in another study to patients who have had a stroke.

The Whitehouse Station, N.J., company is studying vorapaxar for the prevention of cardiac events. Patients with acute coronary syndrome will stop taking it in one study because it reached a pre-determined number of medical issues like cardiovascular deaths, heart attacks or strokes.

A second study will continue with about 75 percent of its patients, minus those who had a stroke either before or during the trial.

The company's shares are down $2.03, or 5.5 percent, to $35.12 in morning trading.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Companies
Shares of Merck Co. are falling after the drugmaker says it has halted one late-stage trial of a potential blood thinner and will immediately stop giving the drug in another study to patients who have had a stroke.The Whitehouse Station, N.J., company is studying...
Merck Drug Trial
119
2011-06-13
Thursday, 13 Jan 2011 12:06 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved